Ratiometric Sensing of Azithromycin and Sulfide Using Dual Emissive Carbon Dots: A Turn On-Off-On Approach
- PMID: 38691279
- DOI: 10.1007/s10895-024-03737-2
Ratiometric Sensing of Azithromycin and Sulfide Using Dual Emissive Carbon Dots: A Turn On-Off-On Approach
Abstract
A novel ratiometric fluorescence probe was developed for the determination of azithromycin (AZM) and sulfide ions based on the differential modulation of red emissive carbon dots (R-N@CDs) and blue emissive carbon dots (B-NS@CDs). The addition of sulfide anion selectively quenched the red emission of R-N@CDs while the blue emission of B-NS@CDs unaffected. Upon subsequent introduction of AZM to this R-N@CDs@sulfide system, the quenched red fluorescence was restored. Comprehensive characterization of the CDs was performed using UV-Vis, fluorescence, FTIR spectroscopy, XPS, and TEM. The proposed method exhibited excellent sensitivity and selectivity, with limits of detection of 0.33 µM for AZM and 0.21 µM for sulfide. Notably, this approach enabled direct detection of sulfide without requiring prior modulation of the CDs with metal ions, as is common in other reported methods. The ratiometric probe was successfully applied for the determination of AZM in biological fluids and sulfide in environmental water samples with high selectivity. This work presents the first fluorometric method for the detection of AZM in biological fluids.
Keywords: Azithromycin; Biological fluids; Carbon dots; Ratiometric; Sulfide.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval: The pharmacokinetic study was conducted in full compliance with ethical regulations, under a protocol approved by the Institutional Animal Care and Use Committee at Assiut University (02/2024/0095). The experiment adhered to the guiding principles in the Helsinki Declaration for humane treatment of animals. Consent to Participate: Not applicable. Consent for publication: Not Applicable. Competing Interests: The authors declare no competing interests.
References
-
- Wilms EB, Touw DJ, Heijerman HGM (2006) Pharmacokinetics of azithromycin in plasma, blood, Polymorphonuclear neutrophils and Sputum during Long-Term Therapy in patients with cystic fibrosis. Ther Drug Monit 28(2). https://doi.org/10.1097/01.ftd.0000195617.69721.a5
-
- Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen Jeanne D, Sharma A (2007) Comparative pharmacokinetics of azithromycin in serum and White Blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-Day Immediate-Release Regimen. Antimicrob Agents Chemother 51(1):103–109. https://doi.org/10.1128/aac.00852-06 - DOI - PubMed
-
- Lalak NJ, Morris DL (1993) Azithromycin Clinical Pharmacokinetics. Clin Pharmacokinet 25(5):370–374. https://doi.org/10.2165/00003088-199325050-00003 - DOI - PubMed
-
- Olupot-Olupot P, Okiror W, Mnjalla H, Muhindo R, Uyoga S, Mpoya A, Williams T, terHeine R, Burger D, Urban B, Connon R, George E, Gibb D, Walker A, Maitland K (2023) Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a phase II randomised controlled trial [version 2; peer review: 2 approved]. 6(161). https://doi.org/10.12688/wellcomeopenres.16968.2
-
- Azithromycin (2016) In: Aronson JK (ed) Meyler’s Side effects of drugs (Sixteenth Edition). Elsevier, Oxford, pp 785–793. doi: https://doi.org/10.1016/B978-0-444-53717-1.00345-0 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
